<DOC>
	<DOC>NCT02045290</DOC>
	<brief_summary>Insulin Clamp Ancillary study for Assessment of Insulin Resistance will be conducted as a sub-study to the main protocol, Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (NCT01881828). The purpose of this ancillary study is to assess if metformin will improve tissue-specific insulin resistance (IR) in type 1 diabetes using a hyperinsulinemic euglycemic clamp; a 3-month randomized trial comparing metformin versus placebo in 12 to &lt;20 year olds with BMI &gt;85th percentile ( total daily insulin dose &gt;0.7 units/kg, and HbA1c 7.0%-9.9%).</brief_summary>
	<brief_title>Insulin Clamp Ancillary Study for Assessment of Insulin Resistance</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1. Meets eligibility criteria of the main study, Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (NCT01881828). 1. Low hemoglobin or hematocrit as defined by each local institution's rules for insulin clamps or if no institutional requirements a Hematocrit &lt;30% or hemoglobin &lt;10 gm/dL</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>